InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.049 0.006 (10.91%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 2026 AGM Letter of Access, Notice of Meeting and Proxy 16 Oct 2026 11:50AM $0.050 $0.049 fallen by 2%
$15 Appendix 4G and Corporate Governance Statement 16 Oct 2026 10:45AM $0.050 $0.049 fallen by 2%
$15 Annual Report to shareholders 16 Oct 2026 10:32AM $0.050 $0.049 fallen by 2%
$15 FDA feedback supports SOF-SKN Phase II plans 8 Oct 2026 8:15AM $0.062 $0.049 fallen by 20.97%
$15 Audited Financial Statements 30 Sep 2026 4:05PM $0.059 $0.049 fallen by 16.95%
$15 SOF-SKN to progress to extension study in CLE patients 14 Sep 2026 8:23AM $0.072 $0.049 fallen by 31.94%
$15 Investor Presentation September 2026 4 Sep 2026 8:11AM $0.080 $0.049 fallen by 38.75%
$15 Novel oligonucleotides data presented at Options Conference 1 Sep 2026 9:36AM $0.089 $0.049 fallen by 44.94%
$15 Appendix 4E - Preliminary Financial Report 28 Aug 2026 4:34PM $0.084 $0.049 fallen by 41.67%
$15 New preclinical data supports immuno-oncology approach 26 Aug 2026 8:06AM $0.095 $0.049 fallen by 48.42%
$15 New study further validates Noxopharms cancer pipeline 4 Aug 2026 8:18AM $0.079 $0.049 fallen by 37.97%
$15 Quarterly Activities/Appendix 4C Cash Flow Report 22 Jul 2026 8:26AM $0.082 $0.049 fallen by 40.24%
$15 Pre-IND meeting request with US FDA 7 Jul 2026 9:34AM $0.094 $0.049 fallen by 47.87%
$15 Sofr platform versatility shown via childbirth MRFF grant 2 Jul 2026 8:15AM $0.085 $0.049 fallen by 42.35%
$15 Fast-tracking of cancer program via novel animal model 1 Jul 2026 9:50AM $0.087 $0.049 fallen by 43.68%
$15 SOF-SKN manufacturing begins to ensure clinical trial readi 9 Jun 2026 8:29AM $0.081 $0.049 fallen by 39.51%
$15 Change of Director's Interest Notice 1 Jun 2026 4:23PM $0.085 $0.049 fallen by 42.35%
$15 New data confirms cancer-fighting potential 26 May 2026 8:21AM $0.060 $0.049 fallen by 18.33%
$15 Noxopharms Sofra assets to be presented at global conference 20 May 2026 9:21AM $0.064 $0.049 fallen by 23.44%
$15 Proposed issue of securities - NOX 8 May 2026 9:28AM $0.072 $0.049 fallen by 31.94%
$15 Noxopharm progresses US regulatory strategy 6 May 2026 8:13AM $0.070 $0.049 fallen by 30%
$15 New data shows SOF-SKN active ingredient efficacy 1 May 2026 9:08AM $0.070 $0.049 fallen by 30%
$15 New Company Secretary appointed 30 Apr 2026 8:18AM $0.077 $0.049 fallen by 36.36%
$15 Innovative collaboration further expands Sofra platform 27 Apr 2026 8:21AM $0.076 $0.049 fallen by 35.53%
$15 March 2026 Quarterly Activities Report and Appendix 4C 24 Apr 2026 9:23AM $0.069 $0.049 fallen by 28.99%

1 - 25 of 804 results

Page 1 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.